United States
Print page content Print
Increase text size Decrease text size
Text Size

ANTISEDAN®

(atipamezole hydrochloride)

Safely reverses the sedative and analgesic effects of DEXDOMITOR in dogs

Antisedan

ANTISEDAN (atipamezole) is indicated for the reversal of the sedative and analgesic effects of DEXDOMITOR® (dexmedetomidine hydrochloride) and DEXDOMITOR® 0.1 (dexmedetomidine hydrochloride).

ANTISEDAN is an α2-antagonist that competitively inhibits α2-adrenergic receptors. It safely and reliably reverses the effects of DEXDOMITOR and DEXDOMITOR 0.1 5–10 minutes after IM injection. Dose volume of administered ANTISEDAN is the same as the preceding dose volume of DEXDOMITOR and 1/5 the dose volume of DEXDOMITOR 0.1

Expand All
    • Benefits of reversal for the practice:
      • Reduces time the dog is sedated and non-ambulatory.
      • Shortens in-clinic stays.
      • Facilitates efficient patient care.
      • Frees up veterinarian and staff.
      • Adds to confidence by allowing quick reversal.
    • Benefits of reversal for the pet owner:
      • The dog returns home awake and ambulatory.
      • Avoids return trip to hospital for owner.
      • Avoids full day or overnight stay for the dog.
      • May reduce costs (compared to hospitalization).
      • Improves client satisfaction.

     

  • Dosing
    Dose volume of administered ANTISEDAN is the same as the preceding dose volume of DEXDOMITOR or 1/5 the dose of DEXDOMITOR 0.1

    Please refer to the full Prescribing Information for additional dosing and administration information.


IMPORTANT SAFETY INFORMATION:
Do not use DEXDOMITOR or DEXDOMITOR 0.1 in dogs or cats, and ANTISEDAN in dogs, with cardiovascular disease, respiratory disorders, liver or kidney diseases, or in conditions of shock, severe debilitation, or stress due to extreme heat, cold or fatigue. DEXDOMITOR and DEXDOMITOR 0.1 should not be administered in the presence of preexisting hypotension, hypoxia, or bradycardia. As with all α2-adrenoceptor agonists, the potential for isolated cases of hypersensitivity, including paradoxical response (excitation), exists with DEXDOMITOR and DEXDOMITOR 0.1. The use of DEXDOMITOR and DEXDOMITOR 0.1 as a preanesthetic in dogs and cats significantly reduces the amount of induction and maintenance anesthetic requirements. Careful patient monitoring is necessary to avoid anesthetic overdose. Arrhythmias, bradycardia, apnea, emesis, convulsions, hypersalivation may occur with DEXDOMITOR and DEXDOMITOR 0.1 use. Severe dyspnea and respiratory crackles due to acute or delayed pulmonary edema could develop in cats. DEXDOMITOR and DEXDOMITOR 0.1 have not been evaluated for use in breeding, pregnant, or lactating dogs or cats; in dogs younger than 16 weeks of age or in cats younger than 12 weeks of age; or in geriatric dogs or cats. Occasional vomiting may occur with ANTISEDAN use. Rarely, a brief state of excitement or apprehensiveness may be seen in ANTISEDAN-treated dogs. Other potential side effects of α2-antagonists, such as ANTISEDAN, include hypersalivation, diarrhea, and tremors. See full Prescribing Information.

ANTISEDAN® is a trademark owned by Orion Corporation and Orion Pharma. It is developed and manufactured by Orion Corporation Orion Pharma Finland and distributed by Zoetis